The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.
Giorgio V. Scagliotti
Honoraria - AstraZeneca; Lilly; Pfizer; Roche
Natasha B. Leighl
No relevant relationships to disclose
Anna K. Nowak
Consultant or Advisory Role - Boehringer Ingelheim
Nick Pavlakis
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Sanjay Popat
Research Funding - Boehringer Ingelheim
Jens Benn Sorensen
No relevant relationships to disclose
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Arsene-Bienvenu Loembe
Employment or Leadership Position - Boehringer Ingelheim
Martha Mueller
Employment or Leadership Position - Boehringer Ingelheim
Ute von Wangenheim
No relevant relationships to disclose
Martin Reck
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche